Bionano Genomics announces peer-reviewed publication on OGM, 523-gene NGS panel

Bionano Genomics announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping, OGM, and a 523-gene next-generation sequencing, NGS, panel for the standard evaluation of myeloid cancers. Medical society guidelines recommend the use of karyotyping, fluorescence in-situ hybridization and sequencing to perform cytogenetic and molecular analysis of patients. The study describes myeloid cancers as posing a significant challenge to manage, with approximately 50% of cases displaying cytogenetically normal genomes, which can confound traditional analysis approaches. “This peer-reviewed publication outlines the potential utility of combining OGM with sequencing panels to evaluate myeloid cancer. I believe this research study shows that OGM can perform significantly better than KT and FISH, which can result in meaningful revisions to various risk classifications and disease stratifications, which are known to affect outcomes. The OGM and sequencing data were analyzed with the upcoming version of our NxClinical analysis software. VIA analysis software will offer a powerful new workflow in cytogenomics and molecular pathology, especially for cancer” commented Erik Holmlin, president and chief executive officer of Bionano.